DUBLIN, January 13, 2021 / PRNewswire / – O “Global Cord Blood Banking Industry Report 2021” report was added to ResearchAndMarkets.com’s offer.
From the early 1900s to the mid-2000s, the global cord blood bank sector proliferated with cord blood banks popping up in all major healthcare markets worldwide. From 2005 to 2010, the market reached saturation and stabilized. From 2010 to 2020, the market started to consolidate aggressively, creating threats and opportunities within the industry.
Serious threats to the sector include low rates of utilization of stored umbilical cord blood, expensive cord blood transplant procedures, difficulty educating obstetricians about cell therapies and an increasing trend towards industry consolidation. Opportunities for industry include price efficiency associated with scale and consolidation, accelerated regulatory pathways for umbilical cord blood and tissue-based cell therapies and progress with ex vivo cell expansion technologies.
Umbilical cord blood industry trends
In recent years, new themes have impacted the industry, including pairing stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including the storage of umbilical cord tissue, placental blood and tissue, amniotic fluid and dental tissue and pulp. Cord blood banks are also investigating ways to become integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, the maturing of the market means that each company is striving more for market share.
An increasing number of investors are also entering the market, with M&A activity accelerating in the US and abroad. Holding companies are emerging as a global theme, allowing for greater operational efficiency and economies of scale. Aryoholdco has established itself as a market leader within Latin America. Founded in 2015, Cryoholdco is a holding company that controls more than a quarter of a million stem cell units (approximately 270,000). It owns half a dozen cord blood banks, as well as a dental stem cell storage company.
Globally, cord blood bank chains have become commonplace, with the Sanpower Group establishing its dominance in Asia. Although Sanpower has been silent about its operations, it holds 4 licenses out of only 7 licenses issued from the cord blood bank at the provincial level in China. He reserved over 900,000 umbilical cord blood samples in China, and its reserves reach more than 1.2 million units when Cordlife’s reserves in Southeast Asian countries are included. This positions Sanpower Group and its subsidiary Nanjing Cenbest as the largest umbilical cord blood bank operator, not only in China and Southeast Asia but in the world.
The number of umbilical cord blood banks in Europe it has dropped by more than a third in the past ten years, from approximately 150 to less than 100. Industry leaders in this market segment include FamiCord Group, which has executed a dozen M&A transactions, and Vita34, which has performed approximately half a dozen. Stemlab, the largest umbilical cord blood bank in Portugal, also ran three acquisition businesses before being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest in the world.
Umbilical cord blood expansion technologies
As the use of cord blood is largely limited to use in pediatric patients, increasing investment is flowing to ex-alivecord blood expansion technologies. If successful, this technology can greatly expand the market potential for umbilical cord blood, encouraging its use in new markets, such as regenerative medicine, aging and increased immunity.
Gamida Cell, Nohla Therapeutics, Excellthera and Magenta Therapeutics currently have ex vivo cord blood expansion products in clinical trials. An increasing number of investors have also entered the umbilical cord blood bank market, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC and Excalibur.
The main questions answered in this report are:
- What strategies are being considered to improve the financial stability of public umbilical cord blood banks?
- What are the complementary products proposed to be developed from umbilical cord blood?
- How much is being spent on processing and storing an umbilical cord blood unit?
- How much does a unit of cryopreserved umbilical cord blood release?
- Why do most public cord blood banks suffer losses?
- What is the net profit margin of a private cord blood bank?
- What are the prices for processing and storing cord blood in private cord blood banks?
- What are the rates per unit of cord blood in the USA and Europe?
- What are the revenues from sales of umbilical cord blood to major umbilical cord blood banks?
- What are the different accreditation systems for umbilical cord blood banks?
- What are the comparative merits of the various cord blood processing technologies?
- What should be done to increase the rate of use of umbilical cord cells in transplants?
- Which TNC counts are preferred for transplantation?
- What is the number of clinical trials registered using blood and cord tissue?
- How many clinical trials are involved in studying the expansion of umbilical cord cells in the laboratory?
- How many compatible and incompatible transplants using umbilical cord blood units are performed annually?
- What is the proportion of umbilical cord cells used for transplantation from 2000 to 2020?
- How likely is it to find a compatible umbilical cord blood unit by ethnicity?
- What are the top ten countries for donating cord blood?
- What are the diseases targeted by MSCs derived from the umbilical cord in clinical trials?
Profiles of selected banks and companies of umbilical cord blood
- AlphaCord LLC
- Americord Registry, Inc.
- Be The Match
- Biocell Center Corporation
- BioEden Group, Inc.
- Biovault Family
- Cellular Care
- Cells4Life Group, LLP
- International Center for Research on Blood and Marrow Transplantation (CIBMTR)
- Cord Blood Center Group
- Cord blood record (CBR)
- Cordlife Group, Ltd.
- Core23 Biobank
- Crio-Cell International, Inc.
- Cryo-Cell International, Inc.
- Cryoviva Biotech Unip. Ltd
- European Society for Bone Marrow and Blood Transplantation (EBMT)
- FamiCord Group
- GeneCell International
- Global Cord Blood Corporation
- HealthBaby Hong Kong
- Insception Lifebank
- LifeCell International Pvt. Ltd.
- Umbilical cord blood laboratories
- MiracleCord, Inc.
- New England Cord Blood Bank, Inc.
- New York Cord Blood Center (NYBC)
- ReeLabs Unip. Ltd.
- Smart Cells International, Ltd.
- Cryobank of stem cells
- StemCyte, Inc.
- Transcell Biolife
- Vita 34 AG
- World Marrow Donor Association (WMDA)
- World Blood and Bone Transplant Network (WBMT)
For more information on this report visit https://www.researchandmarkets.com/r/amvb5q
Research and Markets also offers Custom Search services that provide focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior manager
For E.S.T business hours, call + 1-917-300-0470
For toll free calls in the USA / CAN + 1-800-526-8630
For GMT business hours, call + 353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716
SOURCE Research and Markets